SG11201903008YA - Hla-restricted vgll1 peptides and use thereof - Google Patents
Hla-restricted vgll1 peptides and use thereofInfo
- Publication number
- SG11201903008YA SG11201903008YA SG11201903008YA SG11201903008YA SG11201903008YA SG 11201903008Y A SG11201903008Y A SG 11201903008YA SG 11201903008Y A SG11201903008Y A SG 11201903008YA SG 11201903008Y A SG11201903008Y A SG 11201903008YA SG 11201903008Y A SG11201903008Y A SG 11201903008YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- vgll1
- houston
- apt
- pct
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 101000622237 Homo sapiens Transcription cofactor vestigial-like protein 1 Proteins 0.000 abstract 3
- 102100023478 Transcription cofactor vestigial-like protein 1 Human genes 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/54—Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662405779P | 2016-10-07 | 2016-10-07 | |
PCT/US2017/055414 WO2018067869A1 (en) | 2016-10-07 | 2017-10-05 | Hla-restricted vgll1 peptides and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903008YA true SG11201903008YA (en) | 2019-05-30 |
Family
ID=61831506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903008YA SG11201903008YA (en) | 2016-10-07 | 2017-10-05 | Hla-restricted vgll1 peptides and use thereof |
Country Status (10)
Country | Link |
---|---|
US (1) | US11684657B2 (he) |
EP (1) | EP3522909A4 (he) |
JP (1) | JP2020503840A (he) |
KR (1) | KR20190057130A (he) |
CN (1) | CN110352067A (he) |
AU (1) | AU2017338911B2 (he) |
CA (1) | CA3039541A1 (he) |
IL (1) | IL265834B2 (he) |
SG (1) | SG11201903008YA (he) |
WO (1) | WO2018067869A1 (he) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110637028A (zh) * | 2016-12-29 | 2019-12-31 | 得克萨斯州大学系统董事会 | Hla限制性vcx/y肽和t细胞受体及其用途 |
MX2019010459A (es) | 2017-03-03 | 2020-01-09 | Treos Bio Zrt | Vacuna. |
DE102018112644B4 (de) * | 2018-05-25 | 2020-06-10 | Epiontis Gmbh | CXCR3 als epigenetischer Marker zur Identifizierung von inflammatorischen Immunzellen, insbesondere CD8+ Gedächnis-T-Zellen |
MX2021002449A (es) * | 2018-09-04 | 2021-08-05 | Treos Bio Ltd | Vacunas peptidicas. |
BR112022019454A2 (pt) * | 2020-03-27 | 2022-12-13 | Onecuregen Co Ltd | Composição compreendendo peptídeo vgll1 para tratamento de câncer |
CA3178726A1 (en) | 2020-05-21 | 2021-11-25 | Gregory LIZEE | T cell receptors with vgll1 specificity and uses thereof |
WO2022220632A1 (ko) * | 2021-04-15 | 2022-10-20 | 원큐어젠 주식회사 | 세포 투과 펩티드, 항암 펩티드 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040076955A1 (en) * | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
GB0203420D0 (en) | 2002-02-13 | 2002-04-03 | Oxford Biomedica Ltd | Peptide |
EP2520935A3 (en) | 2006-08-09 | 2013-02-13 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
TWI469791B (zh) | 2009-02-18 | 2015-01-21 | Oncotherapy Science Inc | Foxm1胜肽以及含此胜肽之疫苗 |
DE18200782T1 (de) * | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
US9303079B2 (en) * | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
EP3718556A3 (en) | 2012-08-31 | 2020-12-30 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
KR101714649B1 (ko) * | 2013-10-30 | 2017-03-10 | 한국생명공학연구원 | 암 치료 또는 암 전이 타겟으로서 vgll1의 용도 |
-
2017
- 2017-10-05 SG SG11201903008YA patent/SG11201903008YA/en unknown
- 2017-10-05 WO PCT/US2017/055414 patent/WO2018067869A1/en unknown
- 2017-10-05 US US16/339,981 patent/US11684657B2/en active Active
- 2017-10-05 CN CN201780075407.2A patent/CN110352067A/zh active Pending
- 2017-10-05 KR KR1020197012671A patent/KR20190057130A/ko unknown
- 2017-10-05 JP JP2019518446A patent/JP2020503840A/ja active Pending
- 2017-10-05 EP EP17859215.0A patent/EP3522909A4/en active Pending
- 2017-10-05 CA CA3039541A patent/CA3039541A1/en active Pending
- 2017-10-05 AU AU2017338911A patent/AU2017338911B2/en active Active
- 2017-10-05 IL IL265834A patent/IL265834B2/he unknown
Also Published As
Publication number | Publication date |
---|---|
CA3039541A1 (en) | 2018-04-12 |
EP3522909A4 (en) | 2020-07-08 |
EP3522909A1 (en) | 2019-08-14 |
WO2018067869A1 (en) | 2018-04-12 |
IL265834A (he) | 2019-06-30 |
JP2020503840A (ja) | 2020-02-06 |
WO2018067869A9 (en) | 2019-05-31 |
IL265834B (he) | 2022-11-01 |
US20200040079A1 (en) | 2020-02-06 |
KR20190057130A (ko) | 2019-05-27 |
US11684657B2 (en) | 2023-06-27 |
IL265834B2 (he) | 2023-03-01 |
AU2017338911A1 (en) | 2019-05-02 |
AU2017338911B2 (en) | 2021-09-30 |
CN110352067A (zh) | 2019-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903008YA (en) | Hla-restricted vgll1 peptides and use thereof | |
SG11201908813QA (en) | Anti-sirp alpha antibodies | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201809252YA (en) | Methods for determining dpp3 and therapeutic methods | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201908743SA (en) | Methods and compositions for modulation of immune cells | |
SG11201809594WA (en) | Nicotine particles and compositions | |
SG11201900085TA (en) | Modified ligand-gated ion channels and methods of use | |
SG11201807062RA (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
SG11201806432PA (en) | Methods for assessing risk of developing colorectal cancer | |
SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
SG11201906313SA (en) | A polypeptide linker for preparing multispecific antibodies | |
SG11201806622PA (en) | Egfl6 specific monoclonal antibodies and methods of their use | |
SG11201901925RA (en) | Methods of treating acute kidney injury | |
SG11201805263TA (en) | Compositions and methods for detecting and treating esophageal cancer | |
SG11201908998XA (en) | Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule | |
SG11201900329XA (en) | Combination test for colorectal cancer | |
SG11201805141QA (en) | Compositions and methods for detecting and treating gastric cancer | |
SG11201807478QA (en) | Methods and compositions for increased double stranded rna production |